
Charles River Laboratories (CRL), a mid-cap biotechnology and drugs company, was Validea's highest-rated stock (70%) using Meb Faber's Shareholder Yield Investor model, which prioritizes cash returns to shareholders. Despite this relative ranking, CRL's 70% score falls below the model's 80% 'some interest' threshold. Critically, the company failed specific 'Net Payout Yield' and 'Shareholder Yield' criteria within the strategy, indicating a nuanced fit for a model focused on shareholder returns.
Charles River Laboratories (CRL) scores a 70% rating based on Validea's Shareholder Yield Investor model, a framework developed by Meb Faber that prioritizes cash returns to shareholders. While this is the highest rating for CRL among the 22 guru strategies tracked, the score remains below the model's 80% threshold, which typically signals initial interest. A detailed breakdown reveals a significant contradiction: although the mid-cap biotech firm passes criteria related to 'Quality and Debt', 'Valuation', and 'Relative Strength', it explicitly fails the tests for 'Net Payout Yield' and 'Shareholder Yield'. This indicates that despite possessing other attractive fundamental and momentum characteristics, CRL does not currently align with the core tenets of a strategy focused on direct shareholder cash returns through dividends, buybacks, or debt reduction.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment